

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
1	15/WA/0392	169633	A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)	No		16			13/04/2018	24/06/2019	15/06/2016	23/05/2019	10/07/2019		17/07/2019		
2	16/WS/0114	200445	A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NON-RANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS	No		14			08/05/2019	30/07/2019	27/09/2016	12/08/2019	13/08/2019		28/08/2019		
3	17/SW/0127	225959	A multicentre randomised trial of first line treatment pathways for newly diagnosed immune thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate	No		38			26/07/2018	01/10/2018	03/07/2017	06/11/2018	08/11/2018		20/11/2018	D - Sponsor Delays	Sponsor
4	16/YH/0225	198518	Interactive Binocular Treatment (I-BIT) for the management anisometropic, strabismic and mixed amblyopia in children aged 3.5-9 years.	No		12			29/06/2018	15/11/2018	10/08/2016	12/10/2018	27/11/2018		27/11/2018	F - No patients seen	Neither
5	16/NW/0620	206738	Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) (PRO2TECTCORRECTION)	No		1			14/12/2018	01/04/2019	17/11/2016	20/03/2019	02/04/2019		11/04/2019	F - No patients seen	Neither
6	16/NW/0621	206740	Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) (PRO2TECT-CONVERSION)	No		1			14/12/2018	01/04/2019	21/10/2016	20/03/2019	02/04/2019		11/06/2019	C - Closed by sponsor	Sponsor
7	16/LO/1318	187932	Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance. (NUC-B)	Yes	03/06/2019	69	61	130	22/11/2018	24/01/2019	21/09/2016	28/03/2019	03/04/2019		12/04/2019		
8	16/EE/0065	192416	Survival Improvement with Cholecalciferol in Patients on Dialysis ? The SIMPLIFIED Registry Trial	Yes	07/12/2018	6	10	16	04/05/2017	21/11/2018	29/07/2016	05/11/2018	27/11/2018		28/11/2018		
9	17/LO/0980	219505	Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours	No		21			22/02/2018	17/07/2019	10/07/2017	19/08/2019	07/08/2019		23/08/2019		
10	18/SS/0131	248427	A Randomised Controlled Trial to investigate the effectiveness of Thoracic Epidural and Paravertebral Blockade In reducing Chronic Post- Thoracotomy Pain: 2	Yes	11/02/2019	2	32	34	03/10/2018	08/01/2019	15/11/2018	04/01/2019	10/01/2019		22/01/2019		
11	18/EM/0184	233744	Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH)	No		16			28/11/2018	12/02/2019	04/09/2018	18/02/2019	28/02/2019		05/03/2019		
12	17/EE/0327	224081	A RANDOMISED CONTROLLED TRIAL OF RED CELL REJUVENATION FOR THE ATTENUATION OF TRANSFUSION ASSOCIATED ORGAN INJURY IN CARDIAC SURGERY: The REDJUENATE Trial	No		21			07/02/2017	18/07/2019	20/11/2017	18/01/2018	08/08/2019			D - Sponsor Delays	Sponsor
13	18/LO/0165	224726	POLEM: Avelumab plus 5-FU based chemotherapy as adjuvant treatment for stage 3 MSI-High or POLE exonuclease domain mutant colon cancer: A phase 3 randomised study.	No		26			22/05/2017	13/06/2019	09/05/2018	02/07/2019	09/07/2019		20/09/2019	D - Sponsor Delays	Sponsor
14	16/SW/0232	201854	Rifaximin to Reduce Infection in Decompensated Cirrhosis	No		43			07/08/2018	19/03/2019	31/10/2016	05/06/2019	01/05/2019		07/08/2019	D - Sponsor Delays	Sponsor
15	16/SS/0137	199347	Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)	No		33			14/11/2017	22/02/2019	11/01/2017	20/03/2019	27/03/2019			F - No patients seen	NHS Provider
16	17/SC/0021	219693	The effects of combining electrical stimulation of the calf and thigh muscles in patients with osteoarthritis of the knee	Yes	14/06/2019	5	37	42	21/03/2018	03/05/2019	09/03/2017	02/05/2019	08/05/2019		14/05/2019		
17	17/WM/0110	212527	Paediatric Hepatic International Tumour Trial	No		37			15/02/2017	11/12/2018	28/04/2017	13/12/2018	17/01/2019		01/02/2019	D - Sponsor Delays	Sponsor
18	17/EM/0121	221773	A RANDOMIZED, OPEN, MULTINATIONAL, MULTICENTRE, 2-PART STUDY IN SPONTANEOUSLY BREATHING PRETERM NEONATES WITH MILD TO MODERATE RESPIRATORY DISTRESS SYNDROME TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF INHALED NEBULISED PORACTANT ALFA (PORCINE SURFACTANT, CUROSURF?) IN COMPARISON WITH nCPAP ALONE	Yes	18/06/2019	31	53	84	03/09/2018	26/03/2019	22/05/2017	16/04/2019	26/04/2019		17/06/2019	D - Sponsor Delays	Sponsor

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
19	17/LO/1060	187783	RANDOMISED DOUBLE-BLIND EFFICACY AND MECHANISM STUDY OF SUB-SENSORY SACRAL (OPTIMISED) NEUROMODULATION IN ADULTS WITH FAECAL INCONTINENCE	Yes	12/02/2019	31	82	113	23/04/2018	22/10/2018	29/09/2017	01/11/2018	22/11/2018		27/11/2018	F - No patients seen	Neither
20	18/YH/0396	250694	The Cognition and Flow Study: The Effects of Brain Training on Brain Blood Flow	Yes	22/01/2019	5	8	13	14/08/2018	09/01/2019	08/01/2019	10/01/2019	14/01/2019		14/01/2019		
21	18/YH/0322	226765	Single Use Negative pResure dressing for Reduction In Surgical site infection following Emergency laparotomy	Yes	18/07/2019	36	30	66	18/12/2018	13/05/2019	26/10/2018	13/05/2019	18/06/2019		11/07/2019		
22	18/LO/0513	230722	A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon beta-la) and Placebo in the Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm	No					02/05/2017	21/06/2019	10/10/2018					D - Sponsor Delays	Sponsor
23	17/EM/0440	230556	DANTE: A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma	Yes	30/09/2019	43	111	154	05/02/2018	29/04/2019	18/01/2018	29/05/2019	11/06/2019		18/06/2019		
24	18/EM/0118	217815	Mesothelioma Stratified Therapy (MiST): A stratified multi-arm phase IIa clinical trial to enable accelerated evaluation of targeted therapies for relapsed malignant mesothelioma.	Yes	29/01/2019	7	103	110	28/02/2018	11/10/2018	05/07/2018	15/10/2018	18/10/2018		28/01/2019	D - Sponsor Delays	Sponsor
25	17/SC/0661	227234	Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for post chemo-radiotherapy surveillance in patients with oesophageal cancer ? a feasibility study	Yes	27/06/2019	46	153	199	30/01/2018	10/12/2018	23/01/2018	14/11/2018	25/01/2019		31/01/2019	J - Other	NHS Provider
26	18/WM/0025	233804	Sub-acromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery	Yes	01/08/2019	16	175	191	19/09/2018	22/01/2019	13/02/2018	11/02/2019	07/02/2019		15/02/2019	I - Rare diseases	Neither
27	18/YH/0055	241341	A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant.	Yes	06/09/2019	56	205	261	06/04/2018	19/12/2018	10/05/2018	07/02/2019	13/02/2019		26/02/2019	D - Sponsor Delays	Sponsor
28	18/NE/0296	248487	CArvedilol versus variceal Band ligation in primary pREvention of variceal bleeding in liver cirrhosis	No		0			11/09/2018	24/06/2019	19/10/2018	05/03/2019	24/06/2019		27/09/2019	D - Sponsor Delays	Sponsor
29	18/EM/0120	237879	Study 16113 (0146): This is a phase 3, randomized, global, open-label, efficacy and safety study of REGN2810/chemo-f versus REGN2810/chemo-l/ipi versus standard-of-care platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous NSCLC, whose tumors express PD-L1 in <50% of tumor cells (measured using the PD-L1 IHC 22C3 pharmDx assay) and who have received no prior systemic treatment for their advanced disease.	No					03/02/2018	04/12/2018	19/07/2018					J - Other	Sponsor
30	19/LO/0128	234820	Multicentre prospective double-blind randomised controlled trial of the effect of intravenous iron supplementation, with or without exercise training, in iron-deficient but not anaemic patients with chronic kidney disease on exercise capacity, fatigue, skeletal muscle metabolism and physical function status.	Yes	14/08/2019	5	30	35	16/01/2019	10/07/2019	07/03/2019	07/03/2019	15/07/2019		06/08/2019		
31	18/EM/0189	244758	A randomised placebo-controlled trial of anti-ST2 in COPD (COPD-ST2OP)	Yes	22/10/2018	0	20	20	27/04/2018	02/10/2018	10/08/2018	10/10/2018	02/10/2018		10/10/2018		
32	18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Yes	12/03/2019	16	20	36	13/06/2018	04/02/2019	03/01/2019	07/02/2019	20/02/2019		25/02/2019		
33	17/SC/0536	216069	A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometrial Carcinoma or for disease relapse within 12 months of adjuvant carboplatin-paclitaxel chemotherapy.	Yes	12/09/2019	35	72	107	31/01/2019	28/05/2019	04/12/2017	24/05/2019	02/07/2019		10/07/2019		
34	19/NI/0037	250757	A phase 1, open-label, single dose, non-randomized study to evaluate pharmacokinetics, pharmacodynamics, and safety of Betrixaban in pediatric patients.	Yes	02/10/2019	171	14	185	13/02/2019	31/03/2019	26/03/2019	16/09/2019	18/09/2019		20/09/2019	D - Sponsor Delays	Sponsor

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
35	17/LO/1727	181571	Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents	No					15/05/2018	06/12/2018	26/02/2018					J - Other	Neither
36	17/NW/0637	229352	BiOmarkers in Urine, anTihypeRtensive trEAtment and blood pressure Control in Hypertensive patients - OUTREACH Study	Yes	27/03/2019	20	6	26	22/12/2017	01/03/2019	20/12/2017	08/03/2019	21/03/2019		26/03/2019		
37	18/WA/0199	108978	A randomised, placebo controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants	Yes	09/10/2019	21	2	23	19/06/2018	16/09/2019	29/06/2018	17/09/2019	07/10/2019		08/10/2019		
38	18/YH/0014	224065	External frame versus internal locking plate for articular pilon fracture fixation: a multi-centre randomised controlled trial	Yes	04/09/2019	22	306	328	26/04/2018	11/10/2018	13/02/2018	19/12/2018	02/11/2018		08/01/2019	D - Sponsor Delays	Sponsor
39	18/NE/0125	238346	A three-arm randomised controlled trial to assess the effectiveness and cost-effectiveness of reverse shoulder arthroplasty versus hemiarthroplasty versus non-surgical care for acute three and four- part fractures of the proximal humerus in patients over 65 years of age ? Proximal Fracture Of the Humerus: Evaluation by Randomisation trial No.2 (PROFHER-2).	Yes	29/05/2019	104	93	197	08/12/2017	13/11/2018	15/05/2018	11/02/2019	25/02/2019		25/02/2019	D - Sponsor Delays	Sponsor
40	18/WA/0262	245893	A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)	No		4			29/03/2019	11/07/2019	20/10/2018	07/07/2019	15/07/2019			C - Closed by sponsor	Sponsor
41	18/LO/0204	216147	A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy	Yes	25/06/2019	13	218	231	24/10/2017	06/11/2018	13/04/2018	26/11/2018	19/11/2018		03/12/2018		
42	18/WS/0060	241305	Persistence of inflammation and study of T2 pathways following inhibition of Interleukin-5 with Mepolizumab in severe eosinophilic asthma	Yes	03/06/2019	6	61	67	02/11/2018	28/03/2019	31/10/2018	25/03/2019	03/04/2019		30/04/2019	F - No patients seen	Neither
43	18/LO/0543	242259	An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination, in patients with advanced solid/metastatic tumours.	Yes	17/07/2019	8	56	64	22/01/2019	14/05/2019	12/06/2018	17/05/2019	22/05/2019		03/06/2019		
44	18/SW/0097	241379	Pre-ATNEC - Preoperative tattooing of biopsied axillary node in breast cancer and correlation to sentinel lymph nodes in breast cancer patient	Yes	18/02/2019	59	10	69	18/10/2018	11/12/2018	23/04/2018	08/02/2019	08/02/2019		14/02/2019		
45	18/EE/0099	239606	An open-label, randomised, phase III Study comparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatI colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)	No		38			19/12/2018	16/04/2019	01/06/2018	13/05/2019	24/05/2019		29/05/2019		
46	18/EM/0217	244390	Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure with Heart Failure with Reduced Ejection Fraction	No		34			28/02/2018	08/11/2018	12/09/2018	11/10/2018	12/12/2018		14/01/2019	D - Sponsor Delays	Sponsor
47	19/LO/0384	239240	Magnetic Resonance Imaging (MRI) for Aortic Dissection to Visualise Inflammation.	No		118			02/10/2018	10/05/2019	03/05/2019	10/07/2019	05/09/2019		11/09/2019	D - Sponsor Delays	Sponsor
48	18/WA/0236	245863	Acute rehabilitation following traumatic anterior shoulder dislocation	Yes	22/05/2019	81	103	184	09/03/2018	19/11/2018	08/08/2018	23/11/2018	08/02/2019		08/02/2019	I - Rare diseases	Sponsor
49	18/LO/0555	237992	Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal	No		78			13/06/2019	13/06/2019	19/04/2018	31/07/2019	30/08/2019		15/10/2019	D - Sponsor Delays	Sponsor
50	18/EM/0112	236871	A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.	No		208			12/09/2018	22/11/2018	12/06/2018	31/05/2019	18/06/2019		20/06/2019	E - Staff availability issues	NHS Provider
51	18/EM/0254	246009	A RANDOMISED CONTROLLED TRIAL OF A PRE-OPERATIVE HIGH ENERGY DIET FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: THE PRE-OP ENERGY TRIAL	Yes	07/05/2019	69	41	110	13/03/2018	17/01/2019	27/11/2018	27/03/2019	27/03/2019		28/03/2019		
52	18/EM/0188	246126	A RANDOMISED CONTROLLED TRIAL OF PRE-SURGERY SODIUM VALPROATE, FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: THE Val-CARD TRIAL	Yes	21/11/2018	2	33	35	13/03/2018	17/10/2018	23/08/2018	04/10/2018	19/10/2018		19/10/2018		

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
53	18/SC/0400	245748	A Phase 2, Open-Label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma	No		6			02/02/2018	27/11/2018	16/10/2018	20/11/2018	03/12/2018		20/12/2018		
54	18/EE/0197	246434	A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Yes	15/07/2019	18	56	74	20/11/2018	02/05/2019	10/08/2018	23/04/2019	20/05/2019		03/06/2019	F - No patients seen	Neither
55	19/SC/0021	249552	OPTimal TIMing of Anticoagulation after acute ischaemic Stroke: a randomised controlled trial (OPTIMAS Trial)	No		28			03/04/2019	23/08/2019	04/04/2019	06/09/2019	20/09/2019				
56	18/SC/0243	240684	HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease	Yes	27/08/2019	15	56	71	03/07/2018	17/06/2019	17/10/2018	25/06/2019	02/07/2019		22/08/2019		
57	18/SS/0079	226923	Multi-center, blinded, randomized, PaRallel-group, Phase 3 study with aproCltentan in Subjects with resIstant hypertensIOn.	No		22			08/02/2018	15/07/2019	20/08/2018	15/07/2019	06/08/2019		11/09/2019		
58	18/LO/0122	238790	A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)	Yes	25/03/2019	13	130	143	07/09/2018	02/11/2018	30/04/2018	01/11/2018	15/11/2018		15/11/2018		
59	18/EM/0326	252819	A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma controller (CASCADE)	Yes	02/04/2019	48	103	151	29/08/2018	02/11/2018	17/12/2018	14/12/2018	20/12/2018		14/02/2019	D - Sponsor Delays	Sponsor
60	18/EM/0298	251419	A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis	No		11			25/09/2018	11/02/2019	21/11/2018	14/01/2019	22/02/2019		11/03/2019		
61	18/LO/1522	249494	A prospective, randomised, double-blind, placebo-controlled, multicentre, phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere's disease.	Yes	19/02/2019	7	91	98	02/08/2018	13/11/2018	06/11/2018	15/11/2018	20/11/2018		17/12/2018	F - No patients seen	Neither
62	18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	Yes	04/12/2018	0	49	49	11/06/2018	16/10/2018	18/09/2018	05/10/2018	16/10/2018		16/10/2018		
63	18/EM/0270	232477	The effectiveness of a physical activity intervention versus pulmonary rehabilitation on cardiovascular risk markers for individuals with Chronic Obstructive Pulmonary Disease(PARC)	Yes	18/04/2019	18	136	154	29/08/2018	15/11/2018	02/11/2018	03/12/2018	03/12/2018		03/12/2018	F - No patients seen	Neither
64	18/EE/0282	249797	AN OPEN-LABEL, MULTI-CENTER, PHASE IB STUDY OF RO7082859 AND ATEZOLIZUMAB (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA	Yes	01/04/2019	27	84	111	30/04/2018	11/12/2018	29/10/2018	18/12/2018	07/01/2019		07/01/2019		
65	18/EM/0310	239782	C-Stich2: Emergency Cervical Cerclage to Prevent Miscarriage and Preterm Birth: a Randomised Controlled Trial	No		36			10/12/2018	05/02/2019	16/11/2018	27/02/2019	13/03/2019		14/03/2019	I - Rare diseases	Neither
66	18/WA/0092	230113	Phase II multi-centre, double-blind, randomised trial of Ustekinumab in adolescents with new-onset type 1 diabetes	Yes	24/05/2019	1	80	81	04/10/2018	04/03/2019	21/09/2018	11/02/2019	05/03/2019		01/04/2019	D - Sponsor Delays	Sponsor
67	18/LO/1706	252196	A Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 weeks twice daily oral administration of alvelestat (MPH966) in participants with alpha-1 (PIZZ or null genotype/phenotype) antitrypsin deficiency.	No		82			06/09/2018	13/12/2018	30/11/2018	18/02/2019	05/03/2019		06/03/2019	D - Sponsor Delays I - Rare diseases	Sponsor

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
68	18/EM/0229	250101	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY	Yes	01/03/2019	6	30	36	17/07/2018	24/01/2019	04/10/2018	12/11/2018	30/01/2019		06/02/2019		
69	18/EE/0296	250366	A Phase I, Open Label, Randomized, Parallel Group, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of =40 and =70 mL/min/1.73m2	No		40			03/09/2018	13/02/2019	18/01/2019	19/02/2019	25/03/2019		04/04/2019		
70	18/LO/1606	250789	A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera	No		16			28/11/2018	06/03/2019	05/10/2018	08/03/2019	22/03/2019		02/05/2019	D - Sponsor Delays	Sponsor
71	19/EM/0057	257429	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)	No		11			22/10/2018	20/06/2019	08/05/2019	17/06/2019	01/07/2019		19/09/2019	D - Sponsor Delays	Sponsor
72	18/LO/0430	241907	An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura	Yes	19/08/2019	15	174	189	13/08/2018	11/02/2019	11/06/2018	15/11/2018	26/02/2019		18/07/2019	F - No patients seen	Sponsor
73	19/SW/0140	265506	A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy	No					25/06/2019	25/06/2019	20/08/2019					D - Sponsor Delays	Sponsor
74	18/EM/0336	251477	A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	Yes	07/05/2019	4	57	61	31/05/2018	07/03/2019	19/12/2018	04/03/2019	11/03/2019		13/03/2019		
75	19/WA/0028	233655	Brain TV (Tissue Velocimetry) for emergency assessment of acquired brain injury	Yes	01/08/2019	19	51	70	01/09/2018	23/05/2019	16/05/2019	06/06/2019	11/06/2019		11/06/2019		
76	18/LO/2033	252294	When to Induce Labour to Limit risk in pregnancy hypertension ? a multicentre, randomised controlled trial	No		20			12/03/2019	19/06/2019	10/01/2019	05/07/2019	09/07/2019		10/07/2019		
77	18/WS/0199	253868	A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)	No		224			16/11/2018	11/12/2018	17/12/2018	17/07/2019	23/07/2019		01/08/2019	D - Sponsor Delays E - Staff availability issues	Both
78	18/WM/0324	246654	FORCE - Forearm fracture Recovery in Children Evaluation: A multi-centre prospective randomized equivalence trial of a soft bandage and immediate discharge versus current treatment with rigid immobilisation for torus fractures of the distal radius in children	Yes	20/01/2019	16	44	60	01/11/2018	21/11/2018	16/11/2018	03/12/2018	07/12/2018		16/01/2019	F - No patients seen	Neither
79	19/EM/0031	254100	Understanding the Electrophysiological Substrate in Persistent Atrial Fibrillation - II (USURP AF-study II)	Yes	25/06/2019	44	40	84	03/10/2018	02/04/2019	14/02/2019	16/05/2019	16/05/2019		17/05/2019	F - No patients seen	Neither
80	19/EE/0014	256539	A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, MULTICENTER, 2-PART PHASE II STUDY ON REPLACEMENT OF STEROIDS BY IFX-1 IN ACTIVE GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC POLYANGIITIS (MPA)	No		26			01/06/2018	08/05/2019	02/05/2019	21/05/2019	03/06/2019		05/06/2019		
81	18/LO/2113	240789	Outcomes in children referred for chronic cough and clinical markers for presence of bronchiectasis	Yes	01/02/2019	0	18	18	21/09/2018	14/01/2019	09/01/2019	14/01/2019	14/01/2019		14/01/2019		

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
82	19/LO/0553	257627	GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks	No		69			13/08/2019	13/08/2019	24/09/2019		21/10/2019			D - Sponsor Delays	Sponsor
83	19/SW/0041	260477	A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (anti-PD-1/PD-L1 inhibitor) (LEAP-008)	No		21			19/12/2018	10/06/2019	02/04/2019	21/06/2019	01/07/2019		05/07/2019		
84	19/SW/0093	260867	A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis	No		45			03/10/2018	19/08/2019	17/06/2019	20/09/2019	03/10/2019				
85	18/LO/2140	246772	Post-Market Study to evaluate Real-world outcomes and treatment Practices for the CENTERA? Transcatheter Heart Valve (THV) System	No					01/10/2018	01/02/2019	01/02/2019					H - Contracting delays	Sponsor
86	19/EM/0027	256620	The efficacy of Transcutaneous Electrical Nerve Stimulation versus local anaesthetic cream in alleviating the pain of local anaesthetic injections in adults - A Randomised Controlled Trial	No		71			07/12/2018	15/04/2019	12/03/2019	25/06/2019	25/06/2019		25/06/2019	D - Sponsor Delays	Sponsor
87	19/SC/0151	253737	SMARTHEART validation study - A study to assess the accuracy and validate novel smartphone and wearable ECG devices in cardiovascular patients	No		35			13/11/2018	25/06/2019	17/05/2019	24/07/2019	30/07/2019		30/07/2019		
88	18/SS/0085	243640	Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallelgroup, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost- effectiveness trial with internal pilot (A2B Trial)	Yes	12/04/2019	57	56	113	04/10/2018	20/12/2018	14/12/2018	22/01/2019	15/02/2019		08/04/2019	D - Sponsor Delays	Sponsor
89	19/YH/0026	256695	A first in human, double-blind, placebo-controlled, multicentre Phase I/II study to evaluate the safety, tolerability and immune modulatory effects of MRx-4DP0004 (a lyophilised formulation of Bifidobacterium breve proprietary strain of 4D Pharma Research) in participants taking long-term control medication for their asthma	No		9			19/02/2019	20/05/2019	09/04/2019	16/05/2019	29/05/2019		24/07/2019	D - Sponsor Delays	Sponsor
90	19/EM/0101	260487	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Yes	13/08/2019	0	63	63	15/01/2019	11/06/2019	17/06/2019	06/06/2019	11/06/2019		03/07/2019		
91	19/LO/0285	256948	A Multicenter Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)	Yes	13/08/2019	0	92	92	04/10/2018	13/05/2019	30/04/2019	07/05/2019	13/05/2019		16/05/2019		
92	19/LO/1024	263894	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)	No		56			13/03/2019	02/08/2019	26/07/2019	25/09/2019	27/09/2019			D - Sponsor Delays	Sponsor
93	18/SC/0644	242136	Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study	No					22/02/2019	29/08/2019	19/02/2019						
94	19/YH/0093	255567	A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)	No		98			03/09/2018	08/04/2019	04/06/2019	05/07/2019	15/07/2019		06/08/2019	D - Sponsor Delays	Sponsor
95	REC Exempt	255022	Evaluating the effectiveness of an E-Learning Tool designed to improve the accuracy of visual estimation of maternal blood loss during waterbirth.	No		0			08/04/2019	06/08/2019	30/01/2019	06/08/2019	06/08/2019		06/08/2019		

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
96	19/LO/0361	258316	Bioimpedence In Pregnancy and Labour: A fluid balance concept study (BIPAL study)	Yes	16/04/2019	19	8	27	07/01/2019	20/03/2019	20/03/2019	08/04/2019	08/04/2019		08/04/2019		
97	19/LO/0981	260202	Phase 3 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Relapsed/Refractory HR+/HER2- MBC	No					07/05/2019	20/08/2019	16/08/2019						
98	19/SC/0221	259880	An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies.	No		7			14/02/2019	18/09/2019	10/06/2019	24/09/2019	25/09/2019		04/10/2019		
99	19/LO/0855	260338	A Phase 2, randomized, non-comparative, open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD L1 expression	No		4			13/02/2019	20/09/2019	27/06/2019	11/09/2019	24/09/2019		21/10/2019		
100	19/YH/0049	258945	A PHASE Ic, MULTICENTER, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF A SINGLE DOSE OF MTPS9579A IN PATIENTS WITH ASTHMA REQUIRING INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER	No		50			04/02/2018	11/06/2019	30/05/2019	22/07/2019	31/07/2019		01/08/2019		
101	19/NW/0158	259931	SCIENCE Surgery or Cast for Injuries of the Epicondyle in Children?s Elbows:A multi-centre prospective randomised superiority trial of operative fixation versus non-operative treatment for medial epicondyle fractures of the humerus in children.	Yes	02/07/2019	20	5	25	13/03/2019	07/06/2019	25/03/2019	11/06/2019	27/06/2019		01/07/2019		
102	19/NW/0021	234848	BIOmarker-guided Treatment decisions In Rheumatoid and Psoriatic Arthritis (BIOTIPRA); A Feasibility Study	No		3			07/03/2019	22/07/2019	06/03/2019	22/07/2019	25/07/2019		15/10/2019	D - Sponsor Delays	Sponsor
103	19/YH/0097	261131	Peanut Oral Immunotherapy Study of Early Intervention for Desensitization	No		7			25/02/2019	13/06/2019	28/05/2019	17/06/2019	20/06/2019		03/07/2019		
104	19/EM/0112	259565	Proof-of-mechanism study of QAW039 (fevipirant) in eosinophilic COPD	No		46			25/03/2019	22/04/2019	21/05/2019	03/06/2019	07/06/2019		12/06/2019		
105	19/NE/0235	260081	An International, Phase 3, Multicenter, Randomized, Open Label Trial Comparing Balixafortide In combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer.	No					25/02/2019	23/09/2019	05/09/2019						
106	19/YH/0094	256470	A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR	No		20			30/04/2019	04/07/2019	19/06/2019	27/06/2019	24/07/2019		09/08/2019		
107	19/NW/0181	260431	A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough	No		137			03/04/2019	18/04/2019	14/06/2019	06/08/2019	02/09/2019		10/09/2019	E - Staff availability issues	NHS Provider
108	19/EM/0201	261499	A feasibility study of a multi-centre cluster randomised controlled trial (RCT) to investigate whether a new diagnostic pathway is clinically and cost-effective for older adults presenting with chronic breathlessness.	No		27			22/03/2019	08/08/2019	08/09/2019	19/07/2019	04/09/2019		05/09/2019		
109	19/EM/0060	260387	A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy	No		0			22/01/2019	25/07/2019	11/06/2019	21/06/2019	25/07/2019		01/08/2019		
110	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): A master protocol of two randomised trials to evaluate the non-inferiority of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care	No		88			05/06/2019	06/06/2019	26/07/2019	02/09/2019	02/09/2019			D - Sponsor Delays	Sponsor
111	19/EE/0200	265253	A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients with Type 2 Diabetes (SURPASS-2)	No		28			22/07/2019	03/09/2019	29/07/2019	30/09/2019	01/10/2019				

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
112	19/LO/1270	261294	CRAFT: Cerclarge after full dilatation caesarean section; an investigation into the role of previous in labour caesarean section in future preterm birth risk and potential management strategies	No		14			15/08/2019	26/09/2019	20/09/2019	19/09/2019	10/10/2019				
113	19/LO/0995	263661	To evaluate the acceptability (including gastro intestinal tolerance and compliance) of a hypoallergenic amino acid infant formula with HMOs for the dietary management of cows? milk allergy in infants less than 12 months of age.	No		5			26/07/2019	20/09/2019	24/06/2019	17/09/2019	25/09/2019		26/09/2019		